Sinobiomed currently has two products on the Chinese domestic market.

Wanferon/Wanferin, recombinant human interferon for treating hepatitis B hepatitis C, viral infections and other conditions. Western health experts estimate some 60% of China's 1.3 billion people have been infected with hepatitis B alone at some time in their lives, and 10% are infected now. Chinese officials estimate the disease has infected more than 700 million Chinese. Every year, as many as 400,000 people in China die from liver cancer and other liver ailments caused by the disease.

Leflunomide, a drug for the treatment of rheumatoid arthritis. Leflunomide exhibits both immunomodulatory and anti-inflammatory effects. It not only alleviates symptoms but also prevents disease from progressing. If administered in the early stages, Leflunomide can prevent joint damage and reduce morbidity.

Recombinant Acidic Fibroplast Growth Factor (rh-aFGF) is a Chinese patented treatment for ulceration, deep burns (greater than 2nd degree burns) and chronic ulcers caused by wounds, diabetes, vascular diseases and bedsores. rh-aFGF entered the Chinese market in August 2007 with a production volume of approximately 20 million boxes per year. The Chinese patent will protect rh-aFGF for 20 years from the date of issue in 2004. It will be also be protected as a new drug for seven years, which means that during that period the Chinese Food and Drug Administration (SFDA) will not accept any other company’s new drug application of aFGF in China.